Correlation Between Homology Medicines and ACELYRIN, INC
Can any of the company-specific risk be diversified away by investing in both Homology Medicines and ACELYRIN, INC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Homology Medicines and ACELYRIN, INC into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Homology Medicines and ACELYRIN, INC Common, you can compare the effects of market volatilities on Homology Medicines and ACELYRIN, INC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Homology Medicines with a short position of ACELYRIN, INC. Check out your portfolio center. Please also check ongoing floating volatility patterns of Homology Medicines and ACELYRIN, INC.
Diversification Opportunities for Homology Medicines and ACELYRIN, INC
0.39 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Homology and ACELYRIN, is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Homology Medicines and ACELYRIN, INC Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ACELYRIN, INC Common and Homology Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Homology Medicines are associated (or correlated) with ACELYRIN, INC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ACELYRIN, INC Common has no effect on the direction of Homology Medicines i.e., Homology Medicines and ACELYRIN, INC go up and down completely randomly.
Pair Corralation between Homology Medicines and ACELYRIN, INC
Given the investment horizon of 90 days Homology Medicines is expected to generate 0.81 times more return on investment than ACELYRIN, INC. However, Homology Medicines is 1.24 times less risky than ACELYRIN, INC. It trades about -0.04 of its potential returns per unit of risk. ACELYRIN, INC Common is currently generating about -0.03 per unit of risk. If you would invest 165.00 in Homology Medicines on September 30, 2024 and sell it today you would lose (56.00) from holding Homology Medicines or give up 33.94% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 32.61% |
Values | Daily Returns |
Homology Medicines vs. ACELYRIN, INC Common
Performance |
Timeline |
Homology Medicines |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
ACELYRIN, INC Common |
Homology Medicines and ACELYRIN, INC Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Homology Medicines and ACELYRIN, INC
The main advantage of trading using opposite Homology Medicines and ACELYRIN, INC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Homology Medicines position performs unexpectedly, ACELYRIN, INC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACELYRIN, INC will offset losses from the drop in ACELYRIN, INC's long position.Homology Medicines vs. Passage Bio | Homology Medicines vs. Stoke Therapeutics | Homology Medicines vs. Adaptimmune Therapeutics Plc | Homology Medicines vs. Black Diamond Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Complementary Tools
CEOs Directory Screen CEOs from public companies around the world | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |